Inspections, Compliance, Enforcement, and Criminal Investigations
|
|
- Marcia Reed
- 5 years ago
- Views:
Transcription
1 Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations V-SAB Medical Labs, Inc. 4/26/13 Department of Health and Human Services VIA UNITED PARCEL SERVICE April 26, 2013 Public Health Service Food and Drug Administration 60 Eighth Street, NE Atlanta, GA Telephone: WARNING LETTER 13-ATL-15 Rashid A. Buttar, D.O. President and Chief Operating Officer V-SAB Medical Labs, Inc Torrence Chapel Rd. Suite #204 Dear Dr. Buttar: This letter is in reference to the inspection conducted of your firm, V-SAB Medical Labs, Inc., on May 22, 2012 through June 20, 2012 and your firm s manufacture, marketing, and distribution of the topically administered products: Trans-D Tropin, TD-DMPS, and Progesterone-3/.3. Your products are manufactured, marketed, and distributed in violation the Federal Food, Drug, and Cosmetic Act ( the Act ) as described herein. You promote the aforementioned products on your websites, which include and as well as in YouTube videos and during radio appearances. These websites and media demonstrate that your products are intended for the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or are intended to affect the structure or function of the body of man. Therefore, your products are drugs as defined by section 201(g) of the Act, [21 U.S.C. 321(g)]. Examples of the claims for your products include, but are not limited to, the following: Trans-D Tropin The following statements are located in your Trans-D Tropin product brochure located on your website, through which you sell Trans-D Tropin: Trans-D Tropin is the world s first and only Transdermal Growth Hormone Releasing (GHRH) Analog.... Recent studies show statistically significant increases in hgh levels from baseline, after treatment with Trans-D Tropin. You are a candidate for Trans-D Tropin if you have: Chronic Pain (e.g. Arthritis)... Blood Sugar Abnormalities (hypoglycemia or hyperglycemia) [,] Elevated LDL Cholesterol
2 Page 2 of 5 [,] Reduced HDL Cholesterol... Emotional Instability and/or Depression... Reduced Sex Drive [,] Reduced Sexual Potency/Performance What are some of the Benefits of Trans-D Tropin? Doctors and Patients report... Faster healing and quicker recovery from acute injuries and after surgical procedures... Reduction in chronic pain from old injuries... Renewed interest in sex with enhanced performance and ability... Decrease in anxiety, stress and depression... Decrease in occurrence of general illness due to strengthened immune system TD-DMPS The following statement is located on your TD-DMPS product container label: Indications: May be used by your physician for heavy metal detoxification. Progesterone-3/.3 The following statements are located in your Progesterone-3/.3 product container label and product brochure, respectively: Indications: For use in female hormonal imbalances. Progesterone 3/.3 is indicated in female patients that may be experiencing symptoms of estrogen dominance and/ or adrenal exhaustion. In addition, patients may benefit from the administration of Progesterone 3/.3 if they are seeking to increase bone mass density... prevent or reduce the symptoms of fibrocystic breast disease and uterine fibroids, reduce the symptoms of PMS, improve and maintain the uterine lining (as is beneficial in endometriosis... alleviate depression and anxiety... Furthermore, your various websites contain links to articles and videos about the purported utility of your products. When such references are used commercially by the seller of a product to promote the product to consumers, such references may become evidence of the product s intended uses. A citation of a publication or reference in the labeling of a product is considered to be a claim about the disease treatment or prevention if the citation refers to a disease use, and if the citation implies treatment or prevention of a disease in the context of the labeling as a whole. The following are examples of articles or papers used on your websites to market your products: Buttar, Rashid A. The Inter-relationship between Growth Hormone, IGF 1, and Cancer. Available from 1. Buttar, Rashid A. Position Statement regarding Dr. Buttar s TD-DMPS Treatment Protocol. Available from 2. Bernhoft, Robin and Buttar, Rashid. Autism: A Multi-System Oxidative and Inflammatory Disorder. Townsend Letter April; Available from 3. The intended uses of your products, Trans-D Tropin, TD-DMPS, and Progesterone-3/.3, make clear that they are drugs as defined in section 201(g)(1) of the Act [21 U.S.C. 321(g) (1)]. Moreover, these products are new drugs as defined in section 201(p) of the Act [21 U.S.C. 321(p)] because your drugs are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling. Under section 505(a) of the Act [21 U.S.C. 355(a)], a new drug may not be introduced or delivered for introduction into interstate commerce unless an approved application is in effect for it. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective. The introduction of a drug into interstate commerce that is in violation of 505 is a violation of section 301(d) of the Act [21 U.S.C. 331(d)]. Your products, Trans-D Tropin, TD-DMPS, and Progesterone-3/.3, are also misbranded within the meaning of section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)], in that the labeling fails to
3 Page 3 of 5 bear adequate directions for use. Trans-D Tropin, TD DMPS, and Progesterone.3/3 are considered prescription drugs under section 503(b)(1) of the Act [21 U.S.C. 353(b)(1)] and are not exempt under 21 C.F.R (c)(2) and from the requirement that their labeling bear adequate directions for use because these products lack approved applications. The introduction of a misbranded drug into interstate commerce is a violation of section 301(a) and/or 301(k) of the Act [21 U.S.C. 331(a) and/or 331(k)]. In addition, our investigator(s) identified significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals, Title 21, Code of Federal Regulations, Parts 210 and 211. These violations cause your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the Act [21 U.S.C. 351(a)(2)(B)] in that the methods used in, or the facilities or controls used for, their manufacture, processing, packing, or holding do not conform to, or are not operated or administered in conformity with, CGMP. Our investigator(s) observed specific violations during the inspection, including, but not limited to, the following: CGMP Violations 1. Your firm does not have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 C.F.R (a)). For example, no analytical testing is performed to assess conformance to specifications including the strength of each active pharmaceutical ingredient prior to releasing products for distribution. This is a repeat observation from the 2010 inspection. 2. Your firm failed to conduct at least one specific identity test to verify the identity of each component (21 C.F.R (d)(1)). For example, your firm did not conduct a specific identity test for the progesterone component lot (b)(4) used to manufacture Progesterone-3/.3, lot , on March 5, During the inspection, your lab director confirmed that your firm does not have the instrumentation needed to perform specific identity testing and indicated that (b)(4) was conducted for this component. However, you had no documentation of the (b)(4) test results for progesterone. In your response, provide your plans (e.g., using a contract laboratory) for performing this specific identification test on each incoming component lot, and provisions for addressing inadequate documentation of testing performed by your laboratory. 3. Your firm failed to establish an adequate written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates (21 C.F.R (a)). For example, all of your products are labeled with a 1-year expiration date; however, there is no stability data to support this expiration dating. This is a repeat observation from the 2010 inspection. 4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 C.F.R (b)). For example, your test methods for the determination of total aerobic counts in topically applied products do not include instructions for preparation of media, provisions for the use of positive and negative controls, growth promotion testing, or instructions that require the use of suitable oxygen-permeable bags for incubating your plates.
4 Page 4 of 5 In addition, you have not established adequate specifications for objectionable microorganisms in your drug products based on the products intended use. For example, your topical products should be free of Staphylococcus aureus and Pseudomonas aeruginosa. However, your firm does not test for these organisms, and you have not performed an evaluation of your products to determine the organisms that are objectionable for these products. This is a repeat observation from the 2010 inspection. Repeat citations from prior inspections indicate that your quality control unit is not exercising its responsibilities, and may not have the appropriate authority to carry out its responsibilities. Due to continuing CGMP issues at your firm, if you intend to continue to manufacture drug products we recommend you engage a third party consultant with appropriate CGMP expertise to assess your firm s facility, procedures, processes, and systems to ensure that the drug products you manufacture have their appropriate identity, strength, quality, purity and safety. Your firm, V-SAB Medical Labs, distributes the before-mentioned unapproved new, misbranded, and adulterated drugs in interstate commerce to other physicians and healthcare providers in violation of sections 301(d) and 301(a) of the Act [21 U.S.C. 331(d) and (a)]. You also hold these drugs for use in your own medical practice, SA Buttar Health and Medical, PC (d.b.a. Center for Advanced Medicine and Research) in violation of section 301(k) of the Act [21 U.S.C. 331(k)]. The issues and violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations, with respect to the products specifically identified in this letter and also with respect to all other products that you manufacture. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations. In this regard, please note that products are misbranded under section 502(j) of the Act [21 U.S.C. 352(j)] if they are dangerous to health when used in the dosage or manner; or with the frequency or duration prescribed, recommended, or suggested in the products labeling. You should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in legal action, without further notice, including, without limitation, seizure and injunction. Other federal agencies may take this Warning Letter into account when considering the award of contracts. Please notify this office in writing within fifteen (15) working days from the date you receive this letter of the specific steps you have taken to correct the noted violations. Include an explanation of each step being taken to prevent recurrence of violations as well as any documentation necessary to show that correction has been achieved. If corrective actions cannot be completed within fifteen working days, state the reason for the delay and the time within which you will complete the corrections. Additionally, if another firm manufactures the product identified above, your reply should include the name and address of the manufacturer. If the firm from which you receive the product is not the manufacturer, please include the name of your supplier in addition to the manufacturer. Your written response should be sent to Marie Mathews, Compliance Officer, U.S. Food and Drug Administration, 60 Eighth Street NE, Atlanta, Georgia If you have any questions about this letter please contact Ms. Mathews at (404) or by at marie.mathews@fda.hhs.gov. Sincerely, /S/ John R. Gridley, Director Atlanta District Cc Dean Viktora CEO,
5 Page 5 of 5 AMT/Balance Distribution Torrence Chapel Road Suite #204 Dean Viktora, CEO AMT/Balance Distribution 9815-J Sam Furr Road #230 Huntersville, NC Rashid Buttar, DO West Catawba Avenue Suite 100 Page Last Updated: 05/20/2013 Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players. Accessibility Contact FDA Careers FDA Basics FOIA No Fear Act Site Map Transparency Website Policies U.S. Food and Drug Administration New Hampshire Avenue Silver Spring, MD Ph INFO-FDA ( ) FDA For Government For Press Combination Products Advisory Committees Science & Research Regulatory Information Safety Emergency Preparedness International Programs News & Events Training and Continuing Education Inspections/Compliance State & Local Officials Consumers Industry Health Professionals FDA Archive Links on this page:
TSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17
TSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17 Division of Pharmaceutical Quality Operations IV 19701 Fairchild, Irvine, CA 92612-2506 Telephone: 949-608-2900 Fax: 949-608-4417 WARNING LETTER VIA SIGNATURE
More informationSan Diego Compounding Pharmacy 9/25/17
San Diego Compounding Pharmacy 9/25/17 Division of Pharmaceutical Quality Operations IV 19701 Fairchild Road Los Angeles, CA 92612 WARNING LETTER VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED September
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations P.A. Benjamin Manufacturing
More informationRaritan Pharmaceuticals, Inc. 6/20/17
Raritan Pharmaceuticals, Inc. 6/20/17 U.S. Food & Drug Administration Division of Pharmaceutical Quality Operations I New Jersey District 10 Waterview Boulevard, 3rd Floor Parsippany, NJ 07054 June 20,
More informationReishi D. International, Inc. 2/6/18
Reishi D. International, Inc. 2/6/18 San Francisco District Office 1431 Harbor Bay Parkway Alameda, CA 94502-7070 Via UPS Overnight February 7, 2018 Mr. Zheng Xiong Li, CEO Reishi D. International, Inc.
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations A Nelson & Co.,
More informationStonegate Pharmacy LP 11/10/16
Stonegate Pharmacy LP 11/10/16 November 10, 2016 2017 DAL WL 03 WARNING LETTER UPS Overnight Rene F. Garza, Pharm.D., Chief Executive Officer Stonegate Pharmacy, LP 2501 W. William Cannon Drive, Suite
More informationTown and Country Compounding and Consultation Services, LLC 10/17/17
Town and Country Compounding and Consultation Services, LLC 10/17/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973)
More informationSandoz Inc. 12-Aug-08
Sandoz Inc. 12-Aug-08 Department of Health and Human Services Public Health Service Food and Drug Administration Atlanta District Office 60 8th Street, N.E. Atlanta, Georgia 30309 August 12, 2008 VIA FEDERAL
More informationTalon Compounding Pharmacy 10/3/17
Talon Compounding Pharmacy 10/3/17 Office of Pharmaceutical Quality Operations, Division II 4040 N. Central Expressway, Suite 300 Dallas, Texas 75204 October 3, 2017 CMS Case # 522630 VIA UPS EXPRESS WARNING
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations
More informationHieber's Pharmacy 12/5/17
Hieber's Pharmacy 12/5/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969 CERTIFIED MAIL RETURN RECEIPT REQUESTED
More informationPublic Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA Telephone: 510/
Department of Health and Human Services Public Health Service Food and Drug Administration San Francisco District 1431 Harbor Bay Parkway Alameda, CA 94502-7070 Telephone: 510/337-6700 WARNING LETTER December
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f J Dallas District 4040 North Central Expressway Dallas, Texas 75204-3145 Ref: 2004-DAL-WL-03 WARNING LETTER CERTIFIED MAIL RETURN
More informationRock Solid Nutrition, LLC 12/22/16
Rock Solid Nutrition, LLC 12/22/16 December 22, 2016 WARNING LETTER Kansas City District Office 8050 Marshall Drive - Suite 205 Lenexa, Kansas 66214-1524 913-495-5100 VIA UNITED PARCEL SERVICE OVERNIGHT
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Burzynski Research Institute
More informationPick and Pay Inc dba Cili Minerals 5/8/15
U.S. Food and Drug Administration Protecting and Promoting Your Health Pick and Pay Inc dba Cili Minerals 5/8/15 Department of Health and Human Services Public Health Service Food and Drug Administration
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Dimitri Sirakoff 9/12/13 Department
More informationOpiate Freedom Center 1/11/18
Opiate Freedom Center 1/11/18 UNITED STATES OF AMERICA DEPARTMENT OF HEALTH FEDERAL TRADE COMMISSION AND HUMAN SERVICES BUREAU OF CONSUMER FOOD AND DRUG ADMINISTRATION PROTECTION SILVER SPRING, MD 20993
More informationBetter Health Lab, Inc 2/18/15
U.S. Food and Drug Administration Protecting and Promoting Your Health Better Health Lab, Inc 2/18/15 Department of Health and Human Services Public Health Service Food and Drug Administration New Jersey
More informationOptimum Bioenergy International Corp. 12/21/17
Optimum Bioenergy International Corp. 12/21/17 Office of Human and Animal Food Division 5 West 1431 Harbor Bay Parkway Alameda, CA 94502-7070 Sent Via UPS Signature Required WARNING LETTER December 21,
More informationEden s Answers Inc. and Sprigs Life Inc. 12/14/17
Eden s Answers Inc. and Sprigs Life Inc. 12/14/17 Cincinnati District Office 6751 Steger Drive Cincinnati, OH 45237 Telephone: (513) 679-2700 FAX: (513) 679-2772 December 14, 2017 VIA UPS Overnight Delivery
More informationTheoriginalhcgdrops.com 11/28/11
Theoriginalhcgdrops.com 11/28/11 UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION BUREAU OF CONSUMER PROTECTION WASHINGTON, D.C. 20580 DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION
More informationLopez Gonzalez Santana Corporation dba Domel and dba Dermixx 8/28/17
Lopez Gonzalez Santana Corporation dba Domel and dba Dermixx 8/28/17 Office of Human and Animal Food Operations East Division IV Compliance Branch 466 Avenida Fernández Juncos San Juan, Puerto Rico 00901-3223
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Stanislaw R Burzynski, MD 12/3/13
More informationPublic Health Service Food and Drug Administration Dallas District 4040 North Central Expressway Dallas, Texas
Department of Health and Human Services Public Health Service Food and Drug Administration Dallas District 4040 North Central Expressway Dallas, Texas 75204-3128 March 30, 2010 2010-DAL-WL-08 CERTIFIED
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 9 Inspections, Compliance, Enforcement, and Criminal Investigations Phoenix Medical Devices, LLC 9/29/2009 Department of Health and Human Services Public Health Service Food and Drug Administration
More informationTeva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs
More informationCERTIFIED MAIL RETURN RECEIPT REQUESTED. Esther Hernandez President United States Blood Bank, Inc NW 95th Avenue Miami, Florida
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 CERTIFIED MAIL RETURN RECEIPT REQUESTED Esther Hernandez President United States Blood Bank, Inc. 2400 NW 95th
More information4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch
Libia Lugo Drug Specialist San Juan District Office Investigations Branch The Food and Drug Administration (FDA) responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico,
More informationLong Life Unlimited 1/31/18
Long Life Unlimited 1/31/18 Cincinnati District Office 6751 Steger Drive Cincinnati, OH 45237 Telephone: (513) 679-2700 FAX: (513) 679-2772 WARNING LETTER 533282 January 31, 2018 VIA UPS Long Life Unlimited,
More informationOverview of Dietary Supplement GMP Inspection Trends Quality Session 6
Overview of Dietary Supplement GMP Inspection Trends Quality Session 6 Presented by: Dean R. Cirotta, MBA President & Chief Operating Officer EAS Consulting Group, LLC 1700 Diagonal Road, Suite 750 Alexandria,
More informationTobin's Royal Stag, Inc. dba Tobin Farms Velvet Antler 4/19/17
Tobin's Royal Stag, Inc. dba Tobin Farms Velvet Antler 4/19/17 UNITED PARCEL SERVICE OVERNIGHT DELIVERY April 19, 2017 Darrell Tobin Owner Tobin's Royal Stag, Inc. P.O. Box 108 Alna, ME 04535 0108 Dear
More informationNOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 1401 Rockville Pike Rockville, MD 20852-1448 September 26, 2011 By Overnight Delivery Michael Dean Berger, M.D.
More informationNew England Compounding Center 04-Dec-06
New England Compounding Center 04-Dec-06 Department of Health and Human Services Public Health Service Food and Drug Administration New England District One Montvale Avenue Stoneham, Massachusetts 02180
More informationCase 2:18-cv JTF-dkv Document 1 Filed 09/25/18 Page 1 of 17 PageID 1 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TENNESSEE
Case 2:18-cv-02656-JTF-dkv Document 1 Filed 09/25/18 Page 1 of 17 PageID 1 IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TENNESSEE ) UNITED STATES OF AMERICA, ) ) Civil No: 18-2656 Plaintiff,
More informationNestle Infant Nutrition 10/31/14
U.S. Food and Drug Administration Protecting and Promoting Your Health Nestle Infant Nutrition 10/31/14 OCT 31, 2014 Department of Health and Human Services Public Health Service Food and Drug Administration
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW MEXICO ) ) ) ) ) ) ) ) ) INFORMATION. General Allegations. A. Introduction and Background
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW MEXICO UNITED STATES OF AMERICA, Plaintiff, vs. MOHAMED BASEL ASWAD, M.D., Defendant. CRIMINAL NO. 21 U.S.C. 331(a and 333(a(1: Introduction
More informationApril 30, By Electronic Mail
April 30, 2018 By Electronic Mail Dr. Scott Gottlieb, Commissioner Office of the Commissioner Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 CommissionerFDA@fda.hhs.gov
More informationcgmp (21 CFR 111) Regulation and Compliance Overview
cgmp (21 CFR 111) Regulation and Compliance Overview Neogen Effective Compliance Seminar September 23, 2014 Michael McGuffin President, American Herbal Products Association mmcguffin@ahpa.org Regulation
More informationTruVision Health LLC 11/30/17
TruVision Health LLC 11/30/17 Denver District Office 6 th Ave & Kipling St, Bldg 20 DFC P.O. Box 25087 Denver, CO 80225 November 30, 2017 WARNING LETTER Via UPS Overnight Ref: # HAFW4(DEN)-18-02-WL David
More informationAie Pharmaceuticals Inc 4/17/17
Aie Pharmaceuticals Inc 4/17/17 WARNING LETTER Los Angeles District 19701 Fairchild Road Los Angeles, CA 92612 UNITED PARCEL SERVICE SIGNATURE REQUIRED April 17, 2017 Dr. Magdi Youssef AIE Pharmaceuticals,
More informationPlanning For The FDA s 'Deeming Rule' For E- Cigarettes
Law360, New York (September 21, 2015, 3:39 PM ET) -- The 2009 Family Smoking Prevention and Tobacco Control Act (TCA)[1] gave the U.S. Food and Drug Administration the authority to oversee the manufacture,
More informationSanapac Co., Inc. 3/24/17
Sanapac Co., Inc. 3/24/17 WARNING LETTER 17 PHI 07 PHILADELPHIA DISTRICT U.S. CUSTOMHOUSE 2ND AND CHESTNUT STREETS ROOM 900 PHILADELPHIA, PA 19106 TELEPHONE: 215 597 4390 VIA UNITED PARCEL SERVICE OVERNIGHT
More informationNDA NDA APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 022200 NDA APPROVAL Amylin Pharmaceuticals, Inc. Orville Kolterman, M.D. Sr. Vice President, Research & Development
More informationGenetic Edge Compounds LLC 4/14/17
Genetic Edge Compounds LLC 4/14/17 April 14, 2017 2017 DAL WL 15 UPS Overnight Bradley N. Howard, Owner and CEO Genetic Edge Compounds, LLC (b)(6), (b)(7)(c) McKinney, Texas 75070 Mr. Howard: WARNING LETTER
More informationACTION: Notification; declaratory order; extension of compliance date.
This document is scheduled to be published in the Federal Register on 05/21/2018 and available online at https://federalregister.gov/d/2018-10714, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home > Inspections, Compliance, Enforcement, and Criminal Investigations > Enforcement Actions > Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Punjwani, Sohail S., M.D.
More informationRULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS
RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER 1140-17 DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS 1140-17-.01 Definitions 1140-17-.02 Purpose 1140-17-.03 Eligibility Criteria for Program Participation
More informationAccording to the Indications and Usage section of the FDA-approved product labeling (PI) 1 :
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Rexner Vargas, Senior Manager, Regulatory Affairs Amylin Pharmaceuticals,
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home > Inspections, Compliance, Enforcement, and Criminal Investigations > Enforcement Actions > Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Chawla, Sant P., M.D.
More informationCENTER FOR DRUG EVALUATION AND RESEARCH. APPLICATION NUMBER: Orig1s000 APPROVAL LETTER
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 202107Orig1s000 APPROVAL LETTER DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 202107 NDA APPROVAL
More informationMay 12, 2017 WARNING LETTER
U.S. Food and Drug Administration Seattle District Office 22215 26th Avenue SE, Suite 210 Bothell, Washington 98021 May 12, 2017 OVERNIGHT DELIVERY SIGNATURE REQUIRED In reply refer to WL SEA 17-14 Otto
More informationJune 24, 2008 WARNING LETTER NO NOL-1 9
t DEPARTMENT OF HEALTH AND HUMAN SERVIC E Food and Drug Administration New Orleans District 404 BNA Drive Building 200, Suite 500 Nashville, TN 37217-1003 Telephone : 615-366-7801 Facsimile: 615-366-7802
More informationOverview of FDA Oversight and Enforcement on Drug Compounding
Overview of FDA Oversight and Enforcement on Drug Compounding Ruey Ju, Pharm.D., J.D. Senior Advisor for Compounding Compliance and Enforcement (Acting) Center for Drug Evaluation and Research Today s
More informationNOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)
More informationRed Mill Farms LLC 9/17/15
U.S. Food and Drug Administration Protecting and Promoting Your Health Red Mill Farms LLC 9/17/15 Department of Health and Human Services Public Health Service Food and Drug Administration PHILADELPHIA
More informationUse of Standards in Substantial Equivalence Determinations
Guidance for Industry and for FDA Staff Use of Standards in Substantial Equivalence Determinations Document issued on: March 12, 2000 U.S. Department Of Health And Human Services Food and Drug Administration
More information(Tobacco Control Act), these products are tobacco products because they are made or derived from tobacco and intended for human consumption.
2015 > Knoxville Vapor LLC 4/2/15 (Tobacco Control Act), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Section 301(tt) Violation[1]
More informationCase: 1:18-cv Document #: 1 Filed: 07/26/18 Page 1 of 19 PageID #:1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS
Case: 1:18-cv-05104 Document #: 1 Filed: 07/26/18 Page 1 of 19 PageID #:1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS UNITED STATES OF AMERICA, ) ) Plaintiff, ) ) v. ) ) Civil
More informationNOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)
More informationRE: Permits under the Arizona Pharmacy Act should not be required for dietary supplements
Board Members Arizona State Board of Pharmacy 1616 W. Adams St., Suite 120 Phoenix, AZ 85007 c/o Kam Gandhi, PharmD Executive Director Arizona State Board of Pharmacy Via email: kgandhi@azpharmacy.gov
More informationLevitra According to its FDA-approved product labeling (PI), Levitra is indicated for the treatment of erectile dysfunction.
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Fadwa Almanakly Associate Director, Global Regulatory Affairs Bayer
More informationHome Food Resources for You Consumers. Food
Home Food Resources for You Consumers Food How to Understand and Use the Nutrition Facts Label On this page: The Nutrition Facts Panel - An Overview The Serving Size Calories (and Calories from Fat) The
More informationLIVE INTERACTIVE YOUR DESKTOP. Food Recall Process. Cecilia M. Wolyniak Food and Drug Administration Office of Enforcement
LIVE INTERACTIVE LEARNING @ YOUR DESKTOP Food Recall Process Cecilia M. Wolyniak Food and Drug Administration Office of Enforcement Wednesday, December 9, 2009 LEGAL ISSUES Code of Federal Regulations
More informationQuality. Guaranteeing High Quality. Outsourced Pharmacy Services. Disclosure 3/18/2013
Disclosure Outsourced Pharmacy Services By: Eddie Bostic, RPh For: South Carolina Society of Health System Pharmacist Annual Meeting, March 24 th 2013 Charleston, SC The views and opinions expressed in
More informationDietary Supplement Health and Education Act of 1994 Public Law rd Congress
Dietary Supplement Health and Education Act of 1994 Public Law 103-417 103rd Congress An Act To amend the Federal Food, Drug, and Cosmetic Act to establish standards with respect to dietary supplements,
More informationINTRODUCTION TO DRUG LAW AND REGULATION: REGULATION OF DRUG MANUFACTURING
Food and Drug Law Institute's Workshop on INTRODUCTION TO DRUG LAW AND REGULATION: REGULATION OF DRUG MANUFACTURING November 8-9, 2010 Park Hyatt Hotel Washington, D.C. 1 REGULATION OF DRUG MANUFACTURING
More information7 Food and Drug Administration Via Federa 1 Express Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850
./ + I #~=% @fices.o # Jg DEPARTMENT OF HEACI H & HUMAN SERVICES - Public Health Service : %. % W(-I *4 +4~w.daa 7 Food and Drug Administration Via Federa 1 Express Center for Devices and JAN 25 2001 WARNING
More informationJanuary 7, Dear Ms. Chung:
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 January 7, 2015 Jeisys
More informationFDLI ANNUAL CONFERENCE May 4, 2018
FDLI ANNUAL CONFERENCE May 4, 2018 DIETARY SUPPLEMENTS RETAILER ISSUES AND LIABILITY Jean Frydman, Partner, Chair FDA Practice Fox Rothschild, LLP FDA Concern is Safety Only DHSEA Act of 1994 Know what
More informationMay 7, Dear Mr. Landa:
Ralph A. Simmons 202 429 6459 rsimmons@steptoe.com 1330 Connecticut Avenue, NW Washington, DC 20036-1795 202 429 3000 main www.steptoe.com May 7, 2013 Michael M. Landa Director, Center for Food Safety
More informationGuidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationWARNING LETTER TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Samuel D. Waksal, Ph.D. Chairman and Chief Executive Officer 119
More informationWARNING LETTER. Robert Essner Chairman and Chief Executive Officer Wyeth Pharmaceuticals Inc. P.O. Box 8299 Philadelphia, PA
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Robert Essner Chairman and Chief Executive Officer P.O. Box 8299 Philadelphia,
More informationCase: 5:15-cr DCR-REW Doc #: 1 Filed: 10/01/15 Page: 1 of 15 - Page ID#: 1
Case: 5:15-cr-00087-DCR-REW Doc #: 1 Filed: 10/01/15 Page: 1 of 15 - Page ID#: 1 UNITED STATES OF AMERICA UNITED STATES DISTRICT COURT EASTERN DISTRICT OF KENTUCKY CENTRAL DIVISION LEXINGTON EastemDistr1ot
More informationMarch 8, DxNow, Inc. Kevin Sly Senior Advisor to DxNow, Inc. 401 Professional Drive, Suite 130 Gaithersburg, Maryland
March 8, 2018 Kevin Sly Senior Advisor to 401 Professional Drive, Suite 130 Gaithersburg, Maryland 20879-3429 Re: Trade/Device Name: ZyMot ICSI Sperm Separation Device, ZyMot Multi Sperm Separation Device
More informationNYSW Beverage Brands 1/7/15
8/26/2015 2015 > NYSW Beverage Brands 1/7/15 U.S. Food and Drug Administration Protecting and Promoting Your Health NYSW Beverage Brands 1/7/15 SHARE (HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP? U=HTTP%3A%2F%2FWWW.FDA.GOV%2FICECI%2FENFORCEMENTACTIONS%2FWARNINGLETTERS%2F2015%2FUCM429530.HTM)
More informationDetermining Whether A Dietary Supplement Study Requires an Investigational New Drug (IND)
Determining Whether A Dietary Supplement Study Requires an Investigational New Drug (IND) 02/02/16 description Does a study that claims their dietary supplement promotes healthy joints and cartilage or
More informationIN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA UNITED STATES OF AMERICA v. CRIMINAL NO. UCB, INC., Defendant. VIOLATION 21 U.S.C. 331(k), 352(f)(1), and 333(a)(1) (Causing drugs to be
More informationAgency Information Collection Activities; Submission for Office of Management and Budget
This document is scheduled to be published in the Federal Register on 01/28/2016 and available online at http://federalregister.gov/a/2016-01690, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationBelow is the indication and summary of the most serious and most common risks associated with the use of Naftin Cream, 2%. 2
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Misty M. D Ottavio, Senior Manager Regulatory Affairs 4215 Tudor
More informationSUPPLIER INGREDIENT INFORMATION. 50 lb bag
SUPPLIER INGREDIENT INFORMATION CHOLMONDLEY'S ENGLISH MUFFIN LOAF BASE BRAND: ORTH 3206354-00 Cholmondley's English Muffin Loaf Base is a pre-blended, fully prepared, dry mix base for using in bread applications.
More informationResidual Solvents: FDA/ Regulatory Perspective
Rosa Motta Compliance Officer Residual Solvents: FDA/ Regulatory Perspective PDA/USP Residual Solvents Conference January 18-19, 2007 1 Outline Laws and regulations governing the compliance requirements
More informationSUMMARY: The Food and Drug Administration (FDA) is requesting public input on updated
This document is scheduled to be published in the Federal Register on 11/22/2017 and available online at https://federalregister.gov/d/2017-25245, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationInternational Pharmaceutical Aerosol Consortium on Regulation and Science
International Pharmaceutical Aerosol Consortium on Regulation and Science 1500 K Street NW Washington DC 20005 Telephone +1 202 230 5607 Fax +1 202 842 8465 Email info@ipacrs.org Web www.ipacrs.org Submitted
More informationWARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Carole S. Ben-Maimon, M.D. President and Chief Operating Officer One
More informationCO SPONSORED BY. November 14, 2018 DoubleTree by Hilton Hotel Rochester Rochester, MN
CO SPONSORED BY November 14, 2018 DoubleTree by Hilton Hotel Rochester Rochester, MN Good Manufacturing Practices (GMP) A Regulatory Overview and The Role of EHS in Pharmaceutical Manufacturing Compliance
More informationFSIS DIRECTIVE
UNITED STATES DEPARTMENT OF AGRICULTURE FOOD SAFETY AND INSPECTION SERVICE WASHINGTON, DC FSIS DIRECTIVE 7700.1 2-22-00 I. PURPOSE IRRADIATION OF MEAT AND POULTRY PRODUCTS This directive provides inspection
More informationSouthern California Section & Western Compendial Discussion Group
Association for Official and Analytical Chemists Southern California Section & Western Compendial Discussion Group October 6, 2011 Compliance Officer Bill Vitale, Food and Drug Administration Los Angeles
More informationMEDICNES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF HERBAL MEDICINAL PRODUCTS IN THE GAMBIA
MEDICNES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF HERBAL MEDICINAL PRODUCTS IN THE GAMBIA Document No.: MCA/HMPG/17/12/01 Date of Adoption: 20 th January 2017 Date of Issue: 25 th July 2017 Version
More informationDaniel Fabricant, Ph.D
Daniel Fabricant, Ph.D NIA West Spring Conference May 22, 2018 Who We Are Largest and oldest natural products trade group in U.S. established in 1936 Represent almost 1100 retailers and suppliers of natural
More information510(k) Summary. BioStructures, LLC. Interface Bone Void Filler
I UC7 eacv.4df3 5 10(k) Summary DE 3~ 510(k) Summary BioStructures, LLC September 29, 2011 ADMINISTRATIVE INFORMATION Manufacturer Name: Official Contact: Representative/Consultant: BioStructures, LLC
More informationInspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03
1 of 7 6/10/2009 2:20 PM Inspections, Compliance, Enforcement, and Criminal Investigations Department of Health and Human Services Public Health Service Food and Drug Administration Dallas District 4040
More informationFood Fortification Regulations, 2016 (Gazetted on 24 October, 2016) ARRANGEMENT OF SECTIONS PART I PRELIMINARY
Statutory Instrument 120 of 2016 Food Fortification Regulations, 2016 (Gazetted on 24 October, 2016) [Cap 15:05 Section 1 Title 2 Interpretation ARRANGEMENT OF SECTIONS PART I PRELIMINARY 3 Inspection
More informationCOMMUNITY HOSPICE & PALLIATIVE CARE NOTICE OF PRIVACY PRACTICES
COMMUNITY HOSPICE & PALLIATIVE CARE NOTICE OF PRIVACY PRACTICES THIS NOTICE DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET ACCESS TO THIS INFORMATION. PLEASE
More informationDraft Guidance for Industry and FDA Staff
Draft Guidance for Industry and FDA Staff Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile DRAFT GUIDANCE This guidance document
More informationFOOD AND DRUGS AUTHORITY (FDA) GHANA
REGULATION OF HERBAL MEDICINE IN GHANA FOOD AND DRUGS AUTHORITY (FDA) GHANA 1 PRESENTATION OUTLINE Background Mandate Functions General overview Regulation of Herbal Medicine Cooperation in the ECOWAS
More information